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INTRODUCTION                                                               
Ventricular septal defects (VSD) are the most common congenital cardiac 
defects and account for up to 30% of all congenital cardiac lesions. (1) Post- 
infarction VSDs and trauma are responsible for the acquired forms of 
the defect. 
Haemodynamic effects are related to the size of the left to right shunt and 
vary according to the size of the defect, from negligible to cardiac failure 
and pulmonary hypertension. Some smaller defects have a high likelihood 
of spontaneous closure, whilst larger defects persist through adulthood. 
Long-term complications of VSDs include infective endocarditis, prolapse of 
aortic cusps with regurgitation, arrhythmias and pulmonary hypertension, 
which may lead to Eisenmenger syndrome. 
Percutaneous closure of ventricular septal 
defects in childhood
Surgery is regarded as the golden standard in the management of large 
VSDs. However, percutaneous intervention has progressed markedly over 
the past decade and opened up new avenues of closure for certain VSDs. 
Since Lock used the Rashkind double-umbrella device in 1988 to close 
muscular VSDs, numerous other devices such as coils, Button device, 
Cardioseal and other have been used. (2) Currently, the Amplatzer muscular 
and perimembranous VSD devices are the only occluders specifi cally 
designed for VSD closure and are probably the most universal devices 
implanted for this purpose.
ANATOMY OF A VSD                                                         
Different types of  “simple”  VSDs have been described according to their 
anatomical location. By far the most common are perimembranous VSD 
(70 –80%), muscular VSD (5-10%) and inlet VSD (5-10%). VSD is also an 
element of atrioventricular septal or atrioventricular canal defects (AVSD) 
as well as more complex lesions, but these fall outside the scope of this 
discussion. 
Anderson uses the anatomical relationships as viewed from the right 
ventricle as the primary criterion to describe the defect (3) (see Figure 1). 
The VSDs can thus be placed in three groups:
1. Perimembranous defects – lie adjacent to the area of continuity 
between atrioventricular and arterial valves. 
2. Muscular defects – usually enclosed within the muscular interventricular 
septum and can be between inlet, outlet or apical areas.
3. Doubly committed defects – these are directly related to the aortic and 
pulmonary valves.
It is important to recognise the fact that the membranous septum is directly 
confl uent with the area of fi brous continuity between the aortic and mitral 
valve (as viewed from the left ventricle). It is also related to the fi brous tissue 
that occupies the space between the non-coronary and right coronary 
cusps of the aortic valve. On the right ventricular aspect, the membranous 
septum is crossed by the hinge point of the septal leafl et of the tricuspid 
valve that divides it into atrioventricular and interventricular components. 
This is an important anatomical landmark, since the conduction tissue 
penetrates this septum from the triangle of Koch and then runs in the crest 
of the membranous septum, sandwiched between fi brous and muscular 
septal components.
A defect in the membranous septum should always have the fi brous 
continuity between aortic and tricuspid valves at its posteroinferior margin. 
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Ventricular septal defect is the most common 
congenital cardiac lesion. Surgery was, until recently, the only 
modality of treatment available. Since the fi rst percutaneous closure 
was attempted, new devices have been developed and used to close 
these defects. The procedure is safe and effective if the defects are 
selected correctly with closure being achieved in more than 90% of 
patients. Morbidity and mortality are acceptable and comparable to 
surgery. However, percutaneous ventricular septal defect closure 
is diffi cult, technically challenging and should only be attempted in 





This continuity is an important feature of perimembranous defects. Defects 
should also be described according to their relationships relative to the 
components of the right ventricle, as well as to the valvar components 
(overriding). Perimembranous defects usually extend into the inlet section 
of the right ventricle, but may also extend into the outlet portion of the 
ventricle or may be confl uent, i.e. extending into both inlet and outlet 
components.  When a perimembranous defect extends to communicate 
mostly with the right ventricular inlet, the anterosuperior margin is formed 
by the aortic valve and posteroinferior part by a conjoined area of mitral 
to tricuspid continuity. If a perimembranous defect extends into the outlet 
portions of the ventricle, the medial papillary muscle is related to the 
posterioinferior rim and the outlet septum may be separately recognised. 
Muscular defects may be single or multiple or coexist with other defects. 
An important recognisable feature is the fact that a bar of muscle always 
interposes between the mitral and tricuspid valve hinge points. 
Echocardiographic evaluation of the defects is very important when 
percutaneous closure is considered. General features during transthoracic 
echocardiography are presented in Figures 2 and 3.
VSD CLOSURE                                                                    
Indications for closure
General indications for closure in unrestrictive VSD include symptomatic 
VSD and reversible pulmonary hypertension (pulmonary resistance < 7 
Woods Units). (1-3)  The indications for closure in restrictive VSD are not as 
clear. Most textbooks recommend closure if the pulmonary to systemic shunt 
is (3) 2:1 in patients without the presence of pulmonary hypertension, whilst 
more recent articles suggest a shunt size of > 1,5:1 as an indication for 
closure. (4)    VSD-related complications such as endocarditis or the development 
of aortic regurgitation is also regarded as indication for closure.   Device closure 
should not be attempted in the following: infants < 8 kg, distance less than 
4mm between VSD and valvar structures, pulmonary resistance more than 
7 Woods units or contra-indications to treatment with salisylates. (5) 
Amplatzer VSD devices
The Amplatzer group of VSD devices (AGA Medical Corporation) are 
made of a nickel and Titanium alloy, Nitinol, which consists of 55% nickel 
FIGURE 1: Interventricular septum viewed from right ventricle.
Anatomical location of different types of VSD. P = perimembranous, M = muscular, 







FIGURE 2: Short axis Echocardiogram.
A = perimembranous VSD, B = position of doubly committed VSD
A
B
FIGURE 3: Five Chamber Echocardiographic view.










and 45% titanium. It is essentially a self-expandable wire mesh, comprising 
a central connecting waist and two fl at discs with polyester fabric covering 
the inside (see Figures 4 & 5). 
Three devices for the different defects are available: muscular, membranous 
and post-infarct VSD devices. The membranous VSD occluder has an 
asymmetrical left ventricular disc with a shorter aortic component to avoid 
impingement of the aortic valve, whilst the post-infarct device has a longer 
waist and discs to accommodate the thicker adult interventricular septum. 
The muscular and membranous VSD devices are available in sizes ranging 
from 4-18mm and the post infarct device from 16-24mm. Delivery sheath 
size for muscular and membranous devices range from 6 – 9 French.
Technique
Compared to patent ductus and atrial septal defect closure, VSD closure 
is considerably more complicated. It is thus important to recognise that 
this procedure should only be undertaken in units with suffi cient skill, 
knowledge, adequate equipment and surgical backup.
Complete details of the procedure have been described, (2,6) but a brief 
summary follows. Some variations of the technique occur, dependent on 
the type and location of the VSD. 
The procedure should be performed under general anaesthesia, and 
continuous transoesofageal echocardiography (TEE) is a crucial and integral 
element of percutaneous VSD closure. A complete routine catheterisation 
and angiographic evaluation should be carried out, as well as a thorough 
echocardiographic assessment. Suffi cient time should be spent to obtain 
multiple views at different angles of the VSD, as well as evaluation for 
valvular regurgitation and function.
Access is usually gained via the femoral artery and vein, although the right 
internal jugular vein may be used for certain muscular VSDs. Activated 
clotting time is maintained above 200 seconds throughout the procedure. 
The device selected is usually 1 – 2mm larger than the maximal diameter 
of the defect as assessed by TEE and angiography, although there is a move 
not to exceed the maximum diameter of the defect by much. Balloon sizing 
is hardly ever used, since the interventricular septum is regarded to be a 
non-stretchable structure. 
Normally, the VSD is crossed from the left ventricle using a right coronary 
artery catheter. An exchange guidewire is then placed into the left or right 
pulmonary artery. This guidewire is subsequently snared and exteriorised 
via the femoral vein. The delivery sheath is then advanced via the right 
femoral vein and right ventricle into the aorta. Care should be taken 
to avoid undue tension on the arteriovenous loop and the VSD, as this 
may cause rhythm disturbances and/ or kinking of the sheath. A “kissing” 
catheter technique is used when the VSD is crossed by the sheath to avoid 
direct contact of the guidewire with the VSD. After removal of the dilator, 
the delivery sheath is then gently withdrawn to a safe position in the left 
ventricle. TEE guidance is absolutely vital throughout the procedure.  
The proper sized device is then screwed onto the delivery cable and 
advanced to the tip of the long sheath. Special care should be taken to avoid 
the occurrence of air embolism. The left ventricle disc is then employed 
within the cavity of the left ventricle and gently pulled to the interventricular 
septum. This is done under continuous TEE and intermittent angiographic 
guidance. The waist portion is then deployed, and when in proper position, 
the right ventricular disc. Before release, careful attention should be paid 
to proper positioning of the device. It is also important to establish that 
there is no impingent of valves or other structures. During this period 
the device can still be recaptured into the sheath and repositioned. The 
membranous device has a platinum marker in the left ventricular disc, which 
when properly aligned, should be facing the patient’s feet. Once proper 
positioning has been achieved, the device may be released by unscrewing it 
counter clockwise using the pin vice.  After release, confi rmation of correct 
positioning should be established using TEE and angiography. 
Typically 3 doses of an antibiotic are given and the patient observed for 24 
hours. ECG monitoring should be done during this period.  Endocarditis 
prophylaxis is recommended for 6 months and the patient should receive 
a low dose of an anti-platelet agent or aspirin. 
FIGURE 4: Amplatzer muscular VSD device attached to delivery cable.
FIGURE 5: Simulation of Amplatzer muscular VSD device post-release.
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Other techniques of implantation
The device may also be implanted during surgery as an element of the 
so-called hybrid procedures. This may be accomplished with or without 
cardiopulmonary bypass. Usually the device is implanted by direct perforation 
of the right ventricle under TEE or epicardial echocardiographic guidance.
RESULTS OF PERCUTANEOUS CLOSURE                   
Muscular VSDs
Results largely depend on the type of device used and thus vary widely. 
Successful implantation is usually possible in most patients – 95% according 
to the preliminary European report. (7) Some devices had residual shunts 
ranging from 25 – 60%. As with the ASD devices, early residual leaks are 
common and success is best assessed looking at closure after 12 months. 
Amplatzer muscular occluders were reported to have occlusion rates of up 
to 93% after 12 months. (8-12) Residual shunting that remained was mostly 
classifi ed as trivial.  Residual shunting of varying degrees is also common 
after surgery, occurring in up to 53% of cases. (4)
Perimembranous VSDs
The Amplatzer membranous device is the only device specifi cally designed 
for this lesion. These lesions are technically particularly challenging. 
Satisfactory device impantation is possible in up to 97% of patients with 
a one-year complete closure of between 90 – 100% in reported 
series (5), (12-17) depending on the complexity of the lesion. Recently, muscular 
VSD occluders were used with success to occlude perimembranous VSDs 
in patients with signifi cant aneurysm formation present. (18)
Concerns have been raised whether this is an acceptable alternative to 
surgery, as the complication rate in some studies has been unacceptably 
high, particularly with regard to the development of  heart block. (12 14 16)
COMPLICATIONS                                                              
1.  Haemolysis
This complication is usually associated with residual shunt after attempted 
device closure and may occur in 0.8% of cases. (15) In some instances it may 
be severe and transient renal failure (19) and needs for blood transfusion 
have been described. It has been suggested that it may be minimized by 
soaking the device in the patient’s own blood pre-implantation.
2.  Air embolism
This is an avoidable complication and can easily be avoided by paying 
meticulous attention to technique during catheter and wire exchanges.
3.  Device embolisation
Both systemic and right heart embolisation of the device may occur and 
has been reported in up to 2% of cases. It seems to be related to operator 
experience, and highlights the importance of continuous TEE monitoring 
during the procedure. Operators should be familiar with retrieval 
techniques and all necessary equipment for retrieval should be available. 
Surgical backup is also considered essential.
4.  Valvular regurgitation
The device may infl uence function of any of the valves, but especially with 
the membranous device, aortic and tricuspid regurgitation should actively be 
looked for with TEE prior to release of the device.  It seems that if a minimum 
distance of 4mm from the aortic valve is observed, aortic regurgitation 
usually does not occur.  Signifi cant aortic regurgitation developed in up to 
15% in one series. (5) Mild aortic regurgitation was more common, but some 
of the regurgitation was transient and improved after six months.
5.  Cardiac perforation
Complications of this nature are usually related to catheter and/or guide 
wire perforation of the cardiac chambers. This may lead to pericardial 
effusion, but neither tamponade nor delayed effusion related to the device 
has been described to date.
6.  Dysrhythmias
During catheter and device manipulation temporary dysrhythmias, 
usually ventricular, are common. Right bundle branch block occurred 
in only 6% of patients (5) compared to up to 64% of reported surgical 
series (4, 20).   Complete heart block may also come about during the procedure, 
but cases of delayed development of complete block have been 
described.  Most respond to treatment with steroids and anti-infl ammatory 
agents (21), but permanent pacemaker implantation has also been necessary 
– the latter especially in cases of delayed atrioventricular block. (12) It is 
therefore imperative to have an experienced anaesthetist in theatre during 
the procedure. Knowledgeable personnel should also regularly follow up 
these children. Complete heart block most often follows implantation of 
the membranous VSD device. The exact cause is not known, but local 
trauma with haematoma due to manipulation of catheters and guide 
wires during catheterisation and infl ammatory response to the device or 
mechanical compression due to continued expansion of the device may be 
responsible for complete block, which occurs in up to 3.5% of procedures. 
This compares favourably to surgery, where complete heart block may 
occur in up to 3.1% of children. (4) 
7.  Other
Although rare, serious complications, such as death, have occurred in 
2- 3% of patients. In surgical procedures, death was reported in 0 – 4,3% of 
cases after 1980. (4)  Recently, the fi rst case of endocarditis developing post- 
implantation, which was successfully treated with conservative measures, 
was reported. (22)
POST-INFARCTION VSD                                                   
Post-infarction VSD is a serious complication and without treatment mortality 
may be more than 90%. Even with surgical closure, mortality varies from 
19 – 46%. Closure using percutaneous devices has had promising results, 
although frequently associated with residual shunts. Mortality was comparable 
to surgery (< 28%).  Transcatheter closure of recurrent post-infarction VSD 
following patch repair is currently probably the treatment of choice. (23-25)
CONCLUSION                                                                    
Transcatheter management of ventricular septal defect is now feasible for a 
wide variety of muscular and perimembranous VSDs. The Amplatzer VSD 
devices are specifi cally designed for VSD occlusion and seem effective and 
safe. Other devices, designed for other lesions, should only be considered 
in individual cases. Percutaneous closure should only be attempted on 
properly selected patients in units with suffi cient experience and suitable 
echocardiographic equipment, together with surgical backup. The closure 






Surgical VSD closure remains the golden standard for routine VSD closure 
with a mortality rate of 0 – 2.3%. (26) However, the signifi cant progress in the 
development of percutaneous devices cannot be ignored and in certain 
specifi c settings, like muscular VSDs and post-infarction VSDs, provide for an 
acceptable and attractive alternative treatment.  This might be approached 
as an independent percutaneous intervention or in a hybrid fashion (with 
or without cardiopulmonary bypass).
Peri-operative mortality in the post-infarction VSD group still ranges from 
16 – 49 % and percutaneous closure in these extremely ill patients might 
become the treatment of choice for isolated post-infarction VSD in future. 
The perimembranous group, which constitutes 70% of VSDs, still raises 
concerns. As mentioned above, a 4 mm muscular rim is required, the 
device can impact on (especially) aorta valve function, it cannot be used in 
children of less than 8 kg in weight and it causes heart block in up to 3.2%. 
Heart block incidence after VSD closure is <1%. (27)
The incidence of haemolysis and residual VSD (93% closure at one year), 
remains of concern, as well as device embolisation.
 
The published series of device closures mostly refers to older children with 
weights in excess of 8 kilograms (restrictive VSDs), but exclude small, 
growth compromised children with large VSDs, the “bread and butter” 
referral for surgery. It will be an erroneous belief to postpone surgical 
closure in this group in favour of later device closure.
This is an exciting and potentially very useful development, which we as 
surgeons should approach with an open, though evidence based, mind. 
Author: F.E. Smit
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